Cargando…

Citrullinated Epitopes Identified on Tumour MHC Class II by Peptide Elution Stimulate Both Regulatory and Th1 Responses and Require Careful Selection for Optimal Anti-Tumour Responses

BACKGROUND: Somatic mutations or post-translational modifications of proteins result in changes that enable immune recognition. One such post-translational modification is citrullination, the conversion of arginine residues to citrulline. Citrullinated peptides are presented on MHC class II (MHCII)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Symonds, Peter, Marcu, Ana, Cook, Katherine W., Metheringham, Rachael L., Durrant, Lindy G., Brentville, Victoria A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8630742/ https://www.ncbi.nlm.nih.gov/pubmed/34858415 http://dx.doi.org/10.3389/fimmu.2021.764462

Ejemplares similares

T cell repertoire to citrullinated self-peptides in healthy humans is not confined to the HLA-DR SE alleles; Targeting of citrullinated self-peptides presented by HLA-DP4 for tumour therapy
por: Brentville, Victoria A, et al.
Publicado: (2019)

Citrullinated α-enolase is an effective target for anti-cancer immunity
por: Cook, Katherine, et al.
Publicado: (2017)

PAD-2-mediated citrullination of nucleophosmin provides an effective target for tumor immunotherapy
por: Choudhury, Ruhul H, et al.
Publicado: (2022)

Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responses
por: Brentville, Victoria A, et al.
Publicado: (2020)

Current Strategies to Enhance Anti-Tumour Immunity
por: Cook, Katherine W., et al.
Publicado: (2018)

A Novel HAGE/WT1-ImmunoBody(®) Vaccine Combination Enhances Anti-Tumour Responses When Compared to Either Vaccine Alone
por: Almshayakhchi, Rukaia, et al.
Publicado: (2021)

SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which is further enhanced by checkpoint blockade
por: Xue, Wei, et al.
Publicado: (2016)

SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors
por: Xue, Wei, et al.
Publicado: (2016)

High Avidity Cytotoxic T Lymphocytes Can Be Selected into the Memory Pool but They Are Exquisitely Sensitive to Functional Impairment
por: Brentville, Victoria A., et al.
Publicado: (2012)

Vaccine Can Induce CD4-Mediated Responses to Homocitrullinated Peptides via Multiple HLA-Types and Confer Anti-Tumor Immunity
por: Cook, Katherine, et al.
Publicado: (2022)

Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy
por: Brentville, Victoria Anne, et al.
Publicado: (2022)

Quantitation of MHC antigen expression on colorectal tumours and its association with tumour progression.
por: Durrant, L. G., et al.
Publicado: (1987)

Cancer Vaccines, Adjuvants, and Delivery Systems
por: Paston, Samantha J., et al.
Publicado: (2021)

MHC class II antigen presentation pathway in murine tumours: tumour evasion from immunosurveillance?
por: Walter, W, et al.
Publicado: (2000)

Targeting gp100 and TRP-2 with a DNA vaccine: Incorporating T cell epitopes with a human IgG1 antibody induces potent T cell responses that are associated with favourable clinical outcome in a phase I/II trial
por: Patel, Poulam M., et al.
Publicado: (2018)

Vaccination with post-translational modified, homocitrullinated peptides induces CD8 T-cell responses that mediate antitumor immunity
por: Shah, Sabaria, et al.
Publicado: (2023)

Citrullination only infrequently impacts peptide binding to HLA class II MHC
por: Sidney, John, et al.
Publicado: (2017)

Investigating citrullinated proteins in tumour cell lines
por: Jiang, Zhongmin, et al.
Publicado: (2013)

Homocitrullination of lysine residues mediated by myeloid-derived suppressor cells in the tumor environment is a target for cancer immunotherapy
por: Cook, Katherine W, et al.
Publicado: (2021)

Structural Properties of MHC Class II Ligands, Implications for the Prediction of MHC Class II Epitopes
por: Jørgensen, Kasper Winther, et al.
Publicado: (2010)

Class II transactivator induces expression of MHC-I and MHC-II in transmissible Tasmanian devil facial tumours
por: Ong, Chrissie E. B., et al.
Publicado: (2022)

Predicting MHC class I epitopes in large datasets
por: Roomp, Kirsten, et al.
Publicado: (2010)

IL-21-mediated reversal of NK cell exhaustion facilitates anti-tumour immunity in MHC class I-deficient tumours
por: Seo, Hyungseok, et al.
Publicado: (2017)

Lack of MHC class I antigens and tumour aggressiveness of the squamous cell carcinoma of the larynx.
por: Esteban, F., et al.
Publicado: (1990)

Enhancement of Tumour-Specific Immune Responses In Vivo by ‘MHC Loading-Enhancer’ (MLE)
por: Dickhaut, Katharina, et al.
Publicado: (2009)

Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection.
por: Mongini, C., et al.
Publicado: (1996)

On the biological relevance of MHC class II and B7 expression by tumour cells in melanoma metastases
por: Bernsen, M R, et al.
Publicado: (2003)

Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis
por: Potter, C, et al.
Publicado: (2009)

Modulation of CD8(+) T cell responses to AAV vectors with IgG-derived MHC class II epitopes
por: Hui, Daniel J, et al.
Publicado: (2013)

Discovery of an ancient MHC category with both class I and class II features
por: Okamura, Kazuhiko, et al.
Publicado: (2021)

MHC class I antigens and tumour-infiltrating leucocytes in laryngeal cancer: long-term follow-up.
por: Esteban, F., et al.
Publicado: (1996)

Predictive Models of Tumour Response to Treatment Using Functional Imaging Techniques
por: Marcu, Loredana G., et al.
Publicado: (2015)

Immune response to chemically induced tumours: correlation of responding cell class with in vivo inhibition of tumour growth.
por: Calderwood, M. B., et al.
Publicado: (1981)

Egr2 and 3 maintain anti-tumour responses of exhausted tumour infiltrating CD8 + T cells
por: Symonds, Alistair L. J., et al.
Publicado: (2022)

Fine-specificity of the antibodies against citrullinated protein response is influenced by shared epitope alleles
por: Verpoort, KN, et al.
Publicado: (2007)

Sebaceous tumours: a prototypical class of skin tumour for universal germline genetic testing
por: Gallon, R., et al.
Publicado: (2021)

NetCTLpan: pan-specific MHC class I pathway epitope predictions
por: Stranzl, Thomas, et al.
Publicado: (2010)

HLA-DO as the Optimizer of Epitope Selection for MHC Class II Antigen Presentation
por: Poluektov, Yuri O., et al.
Publicado: (2013)

Characterization of Antigenic MHC-Class-I-Restricted T Cell Epitopes in the Glycoprotein of Ebolavirus
por: Powlson, Jonathan, et al.
Publicado: (2019)

Computational mining of MHC class II epitopes for the development of universal immunogenic proteins
por: Saylor, Kyle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gc63psrsbd88s6m59o6dd3ah0m